After Esperion (ESPR) and Daiichi Sankyo Europe (DSNKY) announced they have reached an amicable resolution regarding the ongoing legal dispute regarding milestone payments pertaining to the companies’ collaboration on bempedoic acid, H.C. Wainwright said the news means the BDA commercialization efforts in Europe can “forge ahead without overhang.” The firm has a Buy rating on Esperion shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ESPR:
- Largest borrow rate increases among liquid names
- U.S. FDA Updates LDL-C Lowering Indication for Esperion’s NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet
- Esperion reinstated with a Neutral at JPMorgan
- Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023
- Esperion presents exploratory analysis of CLEAR Outcomes
